Quest Diagnostics announced it is teaming up with Google Cloud to develop artificial intelligence programs that can personally respond to patients, providers and other customers.
That includes generative AI applications that could “connect employees and customers with enterprise-wide knowledge,” the clinical testing giant said in a statement—in addition to helping patients receive insights from their own lab results.
“Data management has gone through significant generational changes in recent years and is only accelerating today with generative AI,” said Mark Clare, chief data officer at Quest, which cited the collection of more than 80 billion data points from over 200 million test orders in 2024.
That information will be fed into Google Cloud’s HIPAA-compliant infrastructure and managed by Quest's privacy controls. “Quest's relationship with Google will enable Quest to capitalize on the rapidly changing technology landscape to evolve customer insights in a responsible, trusted and secure manner,” Clare said.
Quest has already worked to deploy a hybrid cloud strategy that includes AI and automation approaches in microbiology and cytology testing, as well as specimen processing and customer service, the company said.
Last year, Quest also inked a multi-layered deal with PathAI—acquiring a selection of assets for $100 million in cash, while licensing out others—to establish its own digital R&D solutions center in support of its AmeriPath and Dermpath Diagnostics pathology businesses.